What we do
Public consultation on the EIB Group's Environmental and Social Sustainability Framework - informational webinars
Public consultation on the EIB Group's Environmental and Social Sustainability Framework
The EIF in 2020
Coronavirus: The EIB Group’s initiatives to address its economic consequences
Pan-European Guarantee Fund – EGF
Sustainable Development Umbrella Fund
SDUF Health Compartment
Equity products
AI Co-Investment Facility
Climate & Infrastructure Funds
Technology Transfer
European Angels Fund (EAF) - Co-investments with Business Angels
Venture capital
The Social Impact Accelerator (SIA)
Lower mid-market
Mezzanine Facility for Growth
VentureEU
EFSI Equity instrument
Single EU Equity Financial Instrument
COSME - Equity Facility for Growth
InnovFin Equity
Private equity secondary market transactions
EIF-NPI Equity Platform
ESCALAR Programme
Debt products
New ESIF ERDF Guarantee Fund initiative in Greece
EFSI Private Credit Programme
AGRI Guarantee Facility
AGRI Italy Platform Uncapped Guarantee Instrument
Credit enhancement
Cultural and Creative Sectors Guarantee Facility (CCS GF)
ENSI - Securitisation Initiative
Erasmus+ Master Loan Guarantee Facility
Skills & Education Guarantee Pilot
EREM debt products
Single EU Debt Financial Instrument
Documentary Finance Facility – Bulgaria
The SME Initiative
The SME Initiative Bulgaria
The SME Initiative Finland
The SME Initiative Italy
The SME Initiative Malta
The SME Initiative Romania
The SME Initiative Spain
Inclusive finance
EaSI Financial Instruments
EaSI Capacity Building Investments Window
EaSI Guarantee Instrument
EaSI Funded Instrument
European Progress Microfinance Facility
Entrepreneurs supported through Progress Microfinance
European Fund for Strategic Investments (EFSI)
How does EIF contribute to EFSI
How to apply for EFSI financing
Regional Development - Country and sector-specific initiatives
Dutch Future Fund (DFF)
Dutch Alternative Credit Instrument (DACI)
PORTUGAL BLUE: a new initiative for blue economy investments
JEREMIE Greece Reflows – Business Angels’ Co-Investment Equity Instrument
German Corona Matching Facility (CMF)
Portugal Growth programme
Croatian Growth Investment Programme (CROGIP)
AGRI Italy Platform Uncapped Guarantee Instrument
ALTER’NA – ESIF EARFD Nouvelle-Aquitaine
Baltic Innovation Fund 1 (BIF 1)
Baltic Innovation Fund 2 (BIF 2)
Central Europe Fund of Funds (CEFoF)
Croatian Venture Capital Initiative (CVCi FoF)
Competitiveness Fund-of-Funds for SMEs in Romania
The Cyprus Entrepreneurship Fund (CYPEF)
Cyprus Equity Fund
Deep and Comprehensive Free Trade Area Initiative East Guarantee Facility (DCFTA)
Dutch Growth Co-Investment Programme
Dutch Venture Initiative (DVI-II)
ESIF Fund-of-Funds Greece
EAFRD FoF Portugal
EAFRD FoF Romania
The ERP-EIF Facility
ERP-EIF Co-Investment Growth Facility
The LfA-EIF Facilities
The German Future Fund (GFF) - EIF Growth Facility
INAF – French National Agricultural Initiative
ESIF Energy Efficiency and Renewable Energy Malta
Regional Fund-of-Funds Romania
ESIF Fund-of-Funds Czech Republic
The Silesia EIF Fund of Funds
La Financière Région Réunion
The EIB Group Risk Enhancement Mandate (EREM)
EstFund
FOSTER TPE-PME Occitanie
Greater Anatolia Guarantee Facility (GAGF)
G43 - Anatolian Venture Capital Fund Project
InvestBG Equity Instrument
JEREMIE
JEREMIE Romania Reflows – Equity Instrument
Luxembourg Future Fund (LFF)
Mezzanine 'Fund of Fund' for Germany (MDD)
Polish Growth Fund of Funds (PGFF)
Portugal Venture Capital Initiative (PVCi)
Scottish-European Growth Co-Investment Programme
Slovene Equity Growth Investment Programme (SEGIP)
Swedish Venture Initiative (SVI)
Turkish Growth and Innovation Fund (TGIF)
Western Balkans Enterprise Development & Innovation Facility (WB EDIF)
EAFRD FoF Greece
Irish Innovation Seed Fund (IISF)

Kiro: super-powers through AI

image

“We asked ourselves, why is it that in other areas digital is everywhere, yet in medicine, we are still struggling to make sense of data?” says Alexandre Guenoun, co-founder  and CEO of Kiro (ex-Byond), a French deeptech company that uses artificial intelligence to analyse medical data from clinical laboratories. “Think of finance or trade for example, or advertising – we are able to look at extremely detailed information, analyse at a super-micro-level, and fine-tune our actions. Well, this is what we want to do in medicine.”

Kiro works with patients, medical professionals and laboratories to help them make more sense of lab results and clinical data. “Lab results are often complex to comprehend. You need to simultaneously consider so many different data points and extract useful information while also considering their evolution with time… That could easily be overwhelming for professionals and an unpleasant experience for patients. This is where we bring in artificial intelligence: to help patients with their understanding and to support doctors and clinical biologists in analysing the data faster and more reliably. Laboratory medicine is critical for all decision-making affecting diagnosis or treatment. Our job is not to make decisions nor diagnosis – that’s for healthcare professionals - we ultimately want to give these professionals the super-powers they need so that they can make a more informed decision.”

In late 2019, Kiro received seed financing in the form of an equity investment from Kurma Partners, a venture capital firm backed by the EIF. With this investment, the company was able to hire seven persons and push ahead with developing their product. “We were able to build the first layer of the solution,” explains Alexandre, “and start testing for market fit. Now we’re working on validating it in order to commercialise soon. Healthcare is a very national matter, so we’re focussed on France right now, but we are looking to internationalise and expand to the US in due course.”

In parallel, Kiro has also been active on the Covid-19 front, teaming up with AP-HM hospital group in Marseille on a research project: “We wanted to see if our AI technology could be used to find low-level signals in the Covid pathology. It’s still an early-stage, new pathology - are we able to use AI to better understand its dynamics? Which organs are impacted, what’s happening?” he explains. “I think the most exciting benefit of AI for medicine is the capacity to provide targeted and optimal care at scale. There’s a lot of potential for medicine to grow in this direction, using machine-learning and technology to improve the services of healthcare professionals and, at the end of the day, patient care. We built Kiro to make this happen.”

Company: Kiro (France)

Type of business: AI, healthcare

Financial intermediary: Kurma Partners 

EIF financing: RCR mandate and own resources

For further information about EIF intermediaries in France, please refer to: http://www.eif.org/what_we_do/where/fr/index.htm

 

We use cookies to give the best browser experience on our website. or change cookie settings.

Note: Following the recent withdrawal of the United Kingdom from the European Union, we are updating the relevant EIF.org pages.

 
 

Copyright ©

 European Investment Fund   – The European Investment Fund is not responsible for the content of external internet sites.